Align Technology (NASDAQ:ALGN) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Align Technology (NASDAQ:ALGN) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02, FiscalAI reports. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Align Technology had a return on equity of 16.04% and a net margin of 9.99%.Align Technology’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business earned $2.49 earnings per share.

Here are the key takeaways from Align Technology’s conference call:

• Record Q2 revenue of $1.06 billion rose 4.3% year over year, while clear aligner shipments reached a record 692,000 cases, up 7.4%, led by double-digit growth in APAC, EMEA, and Latin America.
• Clear aligner performance and operational efficiencies lifted non-GAAP operating margin to 22.9%, up 1.6 percentage points year over year, exceeding expectations; full-year non-GAAP operating margin guidance remains approximately 23%.
• Systems and services revenue fell 10.8% to $185.3 million as capital-equipment demand remained soft and customers shifted toward lower-priced scanners, rentals, and leases. Align now expects full-year systems and services revenue to decline 6%–8%.
• Align expects Q3 revenue of $1.00 billion–$1.02 billion, with clear aligner volume growth in the mid-single digits but lower sequential ASPs; Q3 GAAP results will also include approximately $35 million–$50 million of restructuring and accelerated-depreciation charges.
• Following discussions with Elliott Management, Align plans to add three independent directors, conduct a strategic and operating-model review, and increase 2026 share repurchases to approximately $400 million–$500 million, while targeting at least 100 basis points of operating-margin improvement in 2027.

Align Technology Trading Down 3.7%

ALGN opened at $173.41 on Friday. The company has a market cap of $12.42 billion, a P/E ratio of 30.16, a PEG ratio of 1.85 and a beta of 1.67. The company’s 50 day moving average is $174.44 and its 200-day moving average is $175.25. Align Technology has a 1-year low of $122.00 and a 1-year high of $200.43.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ALGN. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a research note on Thursday. Zacks Research cut shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. Leerink Partners upped their price target on shares of Align Technology from $225.00 to $230.00 in a report on Thursday, April 30th. UBS Group reiterated a “neutral” rating and set a $189.00 price target on shares of Align Technology in a research report on Thursday, July 23rd. Finally, Wall Street Zen raised shares of Align Technology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $206.36.

Align Technology News Roundup

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q2 results exceeded expectations: Align reported adjusted earnings of $2.64 per share versus the $2.62 consensus estimate, while revenue reached approximately $1.06 billion versus expectations of $1.05 billion. Revenue increased 4.3% year over year, and earnings rose from $2.49 per share in the prior-year quarter. Align Technology Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Clear-aligner momentum and margins improved: Record Invisalign clear-aligner shipments, digital-workflow expansion, and wider non-GAAP margins provided evidence of operating leverage and continued demand for Align’s core orthodontic products. ALGN Stock Up Post Q2 Earnings and Revenue Beat
• Positive Sentiment: Board and strategic changes may unlock value: Following discussions with Elliott Investment Management, Align will add three independent directors and review its operations. The initiatives could strengthen governance, improve capital allocation, and accelerate efforts to create shareholder value. Align Technology to overhaul board following engagement with Elliott
• Neutral Sentiment: Management reaffirmed its 2026 outlook and highlighted connected digital orthodontics, including Invisalign, iTero scanners, and exocad software, at its 2026 Invisalign Orthodontic Summit. These initiatives support long-term growth but are unlikely to materially change near-term results. Align Technology Hosts 2026 Invisalign Ortho Summit
• Negative Sentiment: Growth and near-term guidance remain concerns: Quarterly revenue guidance was described as slightly below expectations, while scanner pricing pressure and weakness in the systems segment could limit near-term upside. Analysts have maintained a Hold stance, arguing that solid clear-aligner performance has not yet translated into stronger company-wide growth. Align Technology Hold Rating Maintained
• Negative Sentiment: Despite trading well below its 52-week high, valuation-focused commentary says ALGN’s roughly 30 times earnings multiple still requires growth to reaccelerate before a sustained rerating is likely. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up

Institutional Trading of Align Technology

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in shares of Align Technology by 72.0% during the third quarter. Bank of America Corp DE now owns 1,353,125 shares of the medical equipment provider’s stock worth $169,438,000 after buying an additional 566,488 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Align Technology by 65.8% during the 4th quarter. AQR Capital Management LLC now owns 1,196,428 shares of the medical equipment provider’s stock valued at $186,822,000 after acquiring an additional 474,756 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Align Technology by 37.4% during the 3rd quarter. Invesco Ltd. now owns 1,497,535 shares of the medical equipment provider’s stock valued at $187,521,000 after acquiring an additional 407,559 shares in the last quarter. UBS Group AG boosted its holdings in shares of Align Technology by 122.4% during the 3rd quarter. UBS Group AG now owns 581,307 shares of the medical equipment provider’s stock valued at $72,791,000 after acquiring an additional 319,908 shares in the last quarter. Finally, Amundi grew its position in Align Technology by 122.6% during the 3rd quarter. Amundi now owns 558,988 shares of the medical equipment provider’s stock worth $73,507,000 after acquiring an additional 307,898 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology declared that its board has approved a share repurchase program on Wednesday, April 29th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 1.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

About Align Technology

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.